VOR241220P7500
- 0.00
- 0.000.00%
Vor Biopharma Newsroom
Vor Biopharma Price Target Maintained With a $12.00/Share by JMP Securities
Oppenheimer Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $8
Vor Biopharma Reports Promising Phase 1/2 Study Results
Stifel Nicolaus Remains a Buy on Vor Biopharma (VOR)
Vor Bio Reports Promising Clinical Data for Trem-cel + Mylotarg in Acute Myeloid Leukemia Patients Post-Transplant
Vor Bio Presents Data on AML Therapy at ASH 2024 Annual Meeting
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback From FDA Regarding Registrational Trial Design
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
Vor Biopharma's Trem-cel Therapy Shows Promise With Positive Patient Dosing and Upcoming Data Presentation
Vor Biopharma Is Maintained at Outperform by Baird
Express News | HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $17.5 Price Target
Vor Biopharma Analyst Ratings
Barclays Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $3
Barclays Keeps Their Buy Rating on Vor Biopharma (VOR)
Express News | Vor Biopharma Inc : Baird Cuts Target Price to $14 From $22
Express News | Vor Biopharma Q3 EPS $(0.40), Inline
Express News | Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
Press Release: Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
Vor Biopharma | 10-Q: Q3 2024 Earnings Report